INVO Fertility | 8-K: FY2025 Q2 Revenue: USD 1.864 M

Revenue: As of FY2025 Q2, the actual value is USD 1.864 M.

EPS: As of FY2025 Q2, the actual value is USD -13.3.

Revenue

• Total revenue for Q2 2025 was $1,863,654, marking a 1% increase from $1,836,597 in Q2 2024, setting a new quarterly record for the company.
• Consolidated clinic revenue from the INVO Center in Atlanta, Georgia, and the fertility clinic in Madison, Wisconsin, increased by 1% to $1,832,094 from $1,807,921.
• Revenue from all clinics, including both consolidated and equity method clinics, was $2,188,893, a 2% increase from $2,141,229.

Operational Metrics

• Net loss from continuing operations was - $3.2 million, compared to - $2.2 million in the previous year.
• Adjusted EBITDA was - $587,230, compared to - $509,623 in the prior year.
• Total operating expenses increased to $4,853,742 from $3,689,510 in Q2 2024.
• Loss from operations was - $2,990,088, compared to - $1,852,913 in Q2 2024.

Cash Flow

• The report does not provide specific figures for operating cash flow or free cash flow.

Unique Metrics

• The company completed the divestiture of NAYA Therapeutics, Inc., retaining a minority position to potentially benefit from NAYA’s ongoing clinical development.

Outlook / Guidance

• The company is focused on maintaining a highly efficient and scalable operating structure while integrating complementary and accretive revenue-generating businesses and technologies.